Ms. Hamill most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., where she was responsible for approximately $22 billion in annual revenue and an organization of 2,500 employees. In that role she led the transformation of Gilead’s global commercial organization, advancing its structure, governance and capabilities, to return the business to revenue growth. Prior to Gilead, Ms. Hamill spent nearly two decades at Amgen, where she was repeatedly promoted into roles of increasing scope and responsibility in the United States and abroad, leading the international region. As Senior Vice President, U.S. Commercial Operations, she oversaw the business unit representing roughly 80% of company revenue and 2,000 employees across multiple divisions. Throughout her career, Ms. Hamill has built deep expertise in the disciplines most critical to successful commercial launches, including strategic planning, market development, product launches, market access, pricing and contracting, and the design of high-performing commercial organizations. She currently serves on the boards of BB Biotech AG and Jazz Pharmaceuticals. Ms. Hamill holds a Bachelor of Business Administration with an emphasis in marketing from the University of Arizona.